Targeting translation dysregulation in cancer

Dysregulation protein translation in tumor cells may result in the generation and presentation of aberrant peptides that can be exploited for T cell-based therapies.

TO investigate this approach, the researchers deleted tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) in tumor cells and characterized the downstream impact on translation fidelity and immunogenicity,

 TYW2 loss in melanoma cells induces aberrant peptide MHC presentation, increasing both tumor immunogenicity and sensitivity to ICB therapy.  The authors also demonstrate that reduced TYW2 expression is associated with increased response to checkpoint blockade in patients.

The authors believe TYW2 expression levels in patients with melanoma may predict clinical outcomes, highlighting translation regulatory factors as immunotherapy targets.

https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00082-0

https://sciencemission.com/Translation-dysregulation-in-cancer